Novo Nordisk Seeks Court Order to Pull Lilly GLP-1 Ads Over Alleged Misleading Dose Comparisons

Novo files Lanham Act injunction bid against Zepbound/Mounjaro advertising, alleging unfair mg-to-mg dosing comparisons with semaglutide products in a high-stakes duopoly dispute.

ndtv-profit-business · 7/21/2026, 1:02:27 PM · Ask about this →